Sirt1 - sirtuin 1 Gene

中文名称：沉默信息调节因子 2 相关酶类 1

种属: Rattus norvegicus

同用名: Sir2

基因 ID: 309757 | 基因类型: protein coding

关于 Sirt1

Primary_assembly 20: 25,306,917-25,329,260 forward strand.mRatBN7.2:CM026993.1

This gene has 4 transcripts (splice variants), 156 orthologues, 6 paralogues and is associated with 64 phenotypes.

功能概要

该基因编码的蛋白可启动 NAD 依赖性组蛋白脱乙酰酶活性和蛋白激酶 B 结合活性。参与多个过程，包括细胞对酮的反应；细胞凋亡过程的负调控；和肽激素分泌的调节。位于胞质溶胶中；生长锥;和核。用于研究大脑中动脉梗塞；肥胖;骨质疏松症；和 2 型糖尿病。多种疾病的生物标志物，包括急性肾功能衰竭；动脉疾病（多发性）；阳痿;非酒精性脂肪肝病；和肥胖。该基因的人类直系同源物与亨廷顿舞蹈病和前列腺癌有关。与人类 SIRT1（sirtuin 1）同源。 [由基因组资源联盟提供，2022 年 4 月]

Enables NAD-dependent histone deacetylase activity and protein kinase B binding activity. Involved in several processes, including cellular response to ketone; negative regulation of apoptotic process; and regulation of peptide hormone secretion. Located in cytosol; growth cone; and nucleus. Used to study middle cerebral artery infarction; obesity; osteoporosis; and type 2 diabetes mellitus. Biomarker of several diseases, including acute kidney failure; artery disease (multiple); impotence; non-alcoholic fatty liver disease; and obesity. Human ortholog(s) of this gene implicated in Huntington's disease and prostate Cancer. Orthologous to human SIRT1 (Sirtuin 1). [provided by Alliance of Genome Resources, Apr 2022]

Sirt1 基因产物(1)

mRNA	Protein	Name
NM_001372090.1	NP_001359019.1	NAD-dependent protein deacetylase sirtuin-1

基因本体论

分子功能
生物过程
细胞组分

分子功能 GO 注释	逻辑证据	参考文献	来源
enables NAD-dependent histone deacetylase activity	IDA IDA: 通过直接分析推断	19356683	RGD
enables enzyme binding	IPI IPI: 通过物理相互作用推断	19470756	RGD
enables protein kinase B binding	IDA IDA: 通过直接分析推断	23475611	RGD

生物过程 GO 注释	逻辑证据	参考文献	来源
involved in cardiac muscle cell apoptotic process	IMP IMP: 通过突变表型推断	16207712	RGD
involved in cellular response to amyloid-beta	IEP IEP: 通过表达模式推断	23555824	RGD
involved in cellular response to amyloid-beta	IMP IMP: 通过突变表型推断	29358553	RGD
involved in cellular response to antibiotic	IEP IEP: 通过表达模式推断	17581637	RGD
involved in cellular response to curcumin	IEP IEP: 通过表达模式推断	24755072	RGD
involved in cellular response to hydrogen peroxide	IEP IEP: 通过表达模式推断	17581637	RGD
involved in cellular response to organic cyclic compound	IEP IEP: 通过表达模式推断	18538940	RGD
involved in cellular response to resveratrol	IMP IMP: 通过突变表型推断	20089851	RGD
involved in cellular response to rotenone	IEP IEP: 通过表达模式推断	18538940	RGD
involved in cellular response to vitamin B3	IEP IEP: 通过表达模式推断	23555824	RGD
involved in negative regulation of cardiac muscle cell apoptotic process	IMP IMP: 通过突变表型推断	20089851	RGD
involved in negative regulation of fibroblast apoptotic process	IMP IMP: 通过突变表型推断	23479127	RGD
involved in negative regulation of growth hormone secretion	IMP IMP: 通过突变表型推断	23292070	RGD
involved in negative regulation of neuron apoptotic process	IMP IMP: 通过突变表型推断	24755072	RGD
involved in negative regulation of protein acetylation	IMP IMP: 通过突变表型推断	22044919	RGD
involved in negative regulation of protein localization to nucleus	IMP IMP: 通过突变表型推断	22044919	RGD
involved in negative regulation of reactive oxygen species biosynthetic process	IMP IMP: 通过突变表型推断	23422569	RGD
involved in negative regulation of tumor necrosis factor production	IMP IMP: 通过突变表型推断	19299582	RGD
involved in neuron apoptotic process	IMP IMP: 通过突变表型推断	24183892	RGD
involved in positive regulation of cell growth involved in cardiac muscle cell development	IMP IMP: 通过突变表型推断	25281201	RGD
involved in positive regulation of gluconeogenesis	IMP IMP: 通过突变表型推断	21212096	RGD
involved in positive regulation of heart rate	IMP IMP: 通过突变表型推断	22113495	RGD
involved in positive regulation of insulin secretion involved in cellular response to glucose stimulus	IMP IMP: 通过突变表型推断	16366736	RGD
involved in positive regulation of neuron projection development	IMP IMP: 通过突变表型推断	20434449	RGD
involved in positive regulation of protein deacetylation	IMP IMP: 通过突变表型推断	19470756	RGD
involved in positive regulation of skeletal muscle cell proliferation	IMP IMP: 通过突变表型推断	18922599	RGD
involved in positive regulation of thyroid-stimulating hormone secretion	IMP IMP: 通过突变表型推断	20668706	RGD
involved in protein deacetylation	IDA IDA: 通过直接分析推断	19356683	RGD
involved in response to cocaine	IEP IEP: 通过表达模式推断	27664298	RGD
involved in response to ethanol	IDA IDA: 通过直接分析推断	24570955	RGD
involved in response to fluoride	IEP IEP: 通过表达模式推断	24296261	RGD
involved in response to kainic acid	IEP IEP: 通过表达模式推断	18538940	RGD
involved in response to mycotoxin	IEP IEP: 通过表达模式推断	18538940	RGD
involved in response to nutrient levels	IEP IEP: 通过表达模式推断	15205477	RGD
involved in response to resveratrol	IEP IEP: 通过表达模式推断	23555824	RGD
involved in vasodilation	IMP IMP: 通过突变表型推断	23826814	RGD

细胞组分 GO 注释	逻辑证据	参考文献	来源
located in axon	IDA IDA: 通过直接分析推断	23475611	RGD
located in growth cone	IDA IDA: 通过直接分析推断	23475611	RGD
located in nucleus	IDA IDA: 通过直接分析推断	20089851	RGD

EXP：通过实验结果推断 IDA：通过直接分析推断 IPI：通过物理相互作用推断 IMP：通过突变表型推断 IGI：通过遗传相互作用推断 IEP：通过表达模式推断

蛋白主名

其他名称

NAD-dependent protein deacetylase sirtuin-1

NAD-dependent deacetylase sirtuin-1	NAD-dependent protein deacylase sirtuin-1
Sir2alpha	sirtuin 1 ((silent mating type information regulation 2, homolog) 1

相关产品

Approval

生物活性分子 (4)

目录号	产品名	作用方式	纯度	是否罕见病
HY-B0150	Nicotinamide	Inhibitor	99.99%	是
HY-B0879A	Suramin sodium salt	Inhibitor	99.48%	是
HY-B0879	Suramin	Inhibitor	/	否
HY-B0150A	Nicotinamide Hydrochloride	Inhibitor	/	否

Clinical Phase

生物活性分子 (5)

目录号	产品名	作用方式	纯度	Phase
HY-123033A	Nicotinamide riboside chloride	Activator	99.90%	Phase 4
HY-123033	Nicotinamide riboside	Activator	/	Phase 4
HY-123033B	Nicotinamide riboside tartrate	Activator	/	Phase 4
HY-123033C	Nicotinamide riboside malate	Activator	/	Phase 4
HY-15262	SRT 2104	Activator	99.10%	Phase 2

Pre-clinical Phase

生物活性分子 (48)

Cat. No.	产品名	作用方式	纯度	是否罕见病
HY-10532	SRT 1720	Activator	99.90%	否
HY-107454	OSS_128167	Inhibitor	98.63%	否
HY-100578	AGK2	Inhibitor	99.62%	否
HY-15145	SRT 1720 monohydrochloride	Activator	99.92%	否
HY-13515	Sirtinol	Inhibitor	≥98.0%	否
HY-101278	Thiomyristoyl	Inhibitor	99.74%	否
HY-100732	Cambinol	Inhibitor	99.89%	否
HY-N0704	Agrimol B	Activator	99.75%	否
HY-15510	Tenovin-6	Inhibitor	98.33%	否
HY-124037	SRT 1460	Activator	98.16%	否
HY-15869	Inauhzin	Inhibitor	99.49%	否
HY-15145A	SRT 1720 dihydrochloride	Activator	99.13%	否
HY-19759	SRT 2183	Activator	98.17%	否
HY-104073	CAY10602	Activator	98.65%	否
HY-101073	Salermide	Inhibitor	≥98.0%	否
HY-N0341	Scopolin	Activator	99.93%	否
HY-136199	SIRT1-IN-1	Inhibitor	98.19%	否
HY-15452A	(S)-Selisistat	Inhibitor	99.39%	否
HY-N1926	Dihydrocoumarin	Inhibitor	99.81%	否
HY-146689	SIRT1-IN-2	Inhibitor	98.86%	否
HY-16616	SIRT-IN-2	Inhibitor	98.08%	否
HY-117006	E1231	Activator	98.55%	否
HY-15510B	Tenovin-6 Hydrochloride	Inhibitor	98.88%	否
HY-19634	YK-3-237	Activator	99.54%	否
HY-156781	Sirtuin-1 inhibitor 1	Inhibitor	98.09%	否
HY-151519	SIRT2-IN-9	Inhibitor	99.45%	否
HY-122936	Tanshindiol C	Activator	98.47%	否
HY-16615	SIRT-IN-1	Inhibitor	98.58%	否
HY-146690	SIRT1-IN-3	Inhibitor	99.18%	否
HY-148408	SIRT2-IN-11	Inhibitor	99.94%	否
HY-19758A	Sirtuin modulator 1	Modulator	99.85%	否
HY-111329	JGB1741	Inhibitor	99.05%	否
HY-N3504	Ophiopogonin D'	Activator	99.85%	否
HY-111303	CHIC35	Inhibitor	/	否
HY-160617	SIRT2-IN-14	Inhibitor	/	否
HY-N10009	Cudraflavone B	Activator	/	否
HY-148322	Sirtuin modulator 5	Modulator	/	否
HY-123241	ZINC08792229	Inhibitor	/	否
HY-156027	SIRT6-IN-3	Inhibitor	/	否
HY-N9398	3β,6α,12β-Dammar-E-20(22)-ene-3,6,12,25-tetraol	Activator	/	否
HY-E70008	Lumbokinase capsules	Activator	/	否
HY-146013	Sirt1/2-IN-1	Inhibitor	/	否
HY-160944	hsa62	Inhibitor	/	否
HY-148312	Sirtuin modulator 4	Inhibitor	/	否
HY-150727	SIRT5 inhibitor 4	Inhibitor	/	否
HY-N10125	Ainsliadimer C	Activator	/	否
HY-155784	SPC-180002	Inhibitor	/	否
HY-118343	AC-93253	Inhibitor	/	否

直系同源

种属	基因名	来源	基因 ID
Homo sapiens	Sirt1	NCBI	NCBI:23411

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2024 MedChemExpress. All Rights Reserved.

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。

站点地图隐私声明

沪ICP备15051369号-4